DBPR112
CAS No. 1226549-49-0
DBPR112 ( —— )
产品货号. M32878 CAS No. 1226549-49-0
DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂,对 EGFRWT 和 EGFRL858R/T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥590 | 有现货 |
|
| 10MG | ¥914 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥692 | 有现货 |
|
生物学信息
-
产品名称DBPR112
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂,对 EGFRWT 和 EGFRL858R/T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。
-
产品描述DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.
-
体外实验DBPR112 (compound 78; 0.32-1000 nM; 16 hours) induces reduction of phosphorylated EGFR in a dose-dependent manner. DBPR112 shows the inhibitory activity against HCC827 (CC50=25 nM), H1975 (CC50=620 nM) and A431 Cell (CC50=1.02 μM) cell lines. DBPR112 occupies the ATP-binding site and interacts with surrounding residues by covalent bonding, hydrogen bonds, and hydrophobic interactions, which give it a potent inhibitory activity against WT EGFR. Western Blot Analysis Cell Line: H1975 cells Concentration:0.32, 1.6, 8.0, 40, 200, 1000 nM Incubation Time:16 hours Result:Induced reduction of phosphorylated EGFR in a dose-dependent manner in H1975 cells.
-
体内实验DBPR112 (orally; 20-50 mg/kg; 5 days/week for 2 consecutive weeks) significantly reduces tumor growth in HCC827 tumor model. DBPR112 (orally; 50 mg/kg; once a day for 15 days) has a significant antitumor effect (mean tumor growth inhibition of 34%) in H1975 tumor model. DBPR112 (IV; 5 mg/kg) has a T1/2 of 2.3 hours, a CL of 55.6 mL/min?kg, and a Vss of 8.6 L/kg for rats. Animal Model:HCC827 tumor model (6- to 8-week-old athymic NU-Fox1nu nude mice) Dosage:20, 50 mg/kg Administration: Orally; 5 days/week for 2 consecutive weeks (days 1-5 and 8-12)Result:Significantly reduced tumor growth. Animal Model:Rats Dosage:5 mg/kg for IV and 20 mg/kg for PO (Pharmacokinetic Analysis) Administration:IV or PO Result:Had a T1/2 of 2.3 hours, a CL of 55.6 mL/min?kg, and a Vss of 8.6 L/kg by IV. Had a T1/2 of 3.4 hours, a Cmax of 508 ng/mL and an AUC of 2978 ng/mL?h by PO.
-
同义词——
-
通路Angiogenesis
-
靶点EGFR
-
受体EGFR
-
研究领域——
-
适应症——
化学信息
-
CAS Number1226549-49-0
-
分子量533.62
-
分子式C32H31N5O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 250 mg/mL (468.50 mM; 超声助溶 )
-
SMILESCN(C)C\C=C\C(=O)Nc1cccc(c1)-c1c(oc2ncnc(N[C@H](CO)c3ccccc3)c12)-c1ccccc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Lin SY, et al. Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2019 Nov 27;62(22):10108-10123.?
产品手册
关联产品
-
Epidermal Growth Fac...
Epidermal growth factor (EGF) 是促进细胞存活的关键调节因子。Epidermal growth factor (EGF) 信号通路与细胞凋亡 (apoptosis) 有关。Epidermal growth factor (EGF) 的缺失会导致胚胎期或围产期死亡,并伴有多个器官发育异常。Epidermal growth factor (EGF) 可在细胞内短时间里刺激活性氧 (ROS) 的产生。
-
Anlotinib
安罗替尼 (AL-3818) 是一种新型多靶点酪氨酸激酶,主要抑制 VEGFR2/3、FGFR1-4、PDGFR α/β、c-Kit 和 Ret。
-
O-Nornuciferine
O-Nornuciferine 在 HEK293 细胞中显示出明显的体外 hERG 阻断作用,IC50 值为 2.89 uM。
021-51111890
购物车()
sales@molnova.cn

